The Journal of Clinical Psychiatry

BrainsWay Announces Publication of Three New Deep TMS Research Publications

Retrieved on: 
Thursday, August 3, 2023
Medical Affairs Bureau, Suds, TMS, Brainsway, Isabella Tree, Transcranial magnetic stimulation, Innovation, Research, H1, AUD, The Journal of Clinical Psychiatry, Journal, Publication, Patient, Deep, TASE, FDA, Smoking, Mental health, Caregiver, Safety, Medical device, Pharmaceutical industry, H4, List of MDPI academic journals

and JERUSALEM, Aug. 03, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced three recent publications highlighting its Deep Transcranial Magnetic Stimulation (Deep TMS™) in leading peer-reviewed medical journals.

Key Points: 
  • and JERUSALEM, Aug. 03, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced three recent publications highlighting its Deep Transcranial Magnetic Stimulation (Deep TMS™) in leading peer-reviewed medical journals.
  • Two of the publications enhance understanding of the safety profile of TMS.
  • BrainsWay Deep TMS™ for smoking addiction represents the only FDA-cleared TMS solution for any addiction.
  • The publication highlights preliminary research of Deep TMS in various other addictions, and underscores the need for further randomized controlled clinical trials in these difficult-to-treat conditions.

"ResBiotic Publishes Promising Safety and Efficacy Findings from Clinical Trial Study of resB® Lung Support Supplement"

Retrieved on: 
Tuesday, June 13, 2023
MCN, JM, Frontiers, The Journal of Clinical Psychiatry, Pediatrics, LD, International Workshop on Lung Health, Science, FAAP, Clinical trial, Journal, Growth, Probiotic, Dietary supplement, Nutrition, RD, MD

BIRMINGHAM, Ala., June 12, 2023 /PRNewswire/ -- ResBiotic Nutrition Inc (ResBiotic) announced today that its latest peer-reviewed clinical trial featuring resB® Lung Support has been published in Frontiers in Nutrition. The study, titled "Clinical Trial of a Probiotic and Herbal Supplement for Lung Health," yielded significant results, including improvements in lung functions and in quality of life scores in participants. Overall, most participants were highly likely to recommend resB®. resB® Lung Support, as a product target anyone concerned about their respiratory or lung health. In addition, users of resB® see significant gut health and immune benefits similar to other high potency probiotics.

Key Points: 
  • BIRMINGHAM, Ala., June 12, 2023 /PRNewswire/ -- ResBiotic Nutrition Inc (ResBiotic) announced today that its latest peer-reviewed clinical trial featuring resB® Lung Support has been published in Frontiers in Nutrition.
  • The study, titled " Clinical Trial of a Probiotic and Herbal Supplement for Lung Health ," yielded significant results, including improvements in lung functions and in quality of life scores in participants.
  • resB® Lung Support, as a product target anyone concerned about their respiratory or lung health.
  • Adding, "Each ingredient in resB® Lung Support has been validated and tested for efficacy in several studies, and we are launching similar science backed products to our portfolio this year".

Neuronetics Reports Record Fourth Quarter and Record Full Year 2022 Financial and Operating Results

Retrieved on: 
Tuesday, March 7, 2023
Partnership, Mental, Journal, Neuronetics, Major depressive disorder, Publication, Development, Anxiety, Depression, Collaboration, CT, Telephone, Network, Webcast, Patient, ME, MA, Research and development, The Journal of Clinical Psychiatry, Marketing, Research, DSM-IV codes, Policy, NGS, Travel, RI, MDD, TMS, Cryptocurrency, Video game, Pharmaceutical industry, EBITDA

For the period ended December 31, 2022 and 2021, the Company shipped 213 and 147 systems, respectively.

Key Points: 
  • For the period ended December 31, 2022 and 2021, the Company shipped 213 and 147 systems, respectively.
  • Operating expenses during the full year 2022 were $84.8 million, an increase of $13.6 million, or 19.1%, compared to $71.2 million in the full year 2021.
  • See the accompanying financial table that reconciles EBITDA, which is a non-GAAP financial measure, to net loss.
  • To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Neuronetics’ website at ir.neuronetics.com .

Teva Announces Publication of New Clinician Scale in Journal of Clinical Psychiatry to Assess the Impact of Tardive Dyskinesia on Patients’ Lives

Retrieved on: 
Thursday, February 23, 2023
Pharmaceutical, Health, Mental Health, TEVA, Doctor of Philosophy, TD, MD, University, Teva Pharmaceuticals, NYSE, Journal, Patient, Torso, Tardive dyskinesia, Face, Medication, TASE, Caregiver, Psychiatry, Mental health, University of Michigan School of Social Work, The Journal of Clinical Psychiatry, Nursing, Teva

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the print publication of the IMPACT-TD Scale, an easy-to-use, standardized and clinician-rated assessment.

Key Points: 
  • Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the print publication of the IMPACT-TD Scale, an easy-to-use, standardized and clinician-rated assessment.
  • The scale, developed by a consensus panel, will assist healthcare providers in determining the impact of tardive dyskinesia (TD) on different aspects of a patient’s daily functioning.
  • IMPACT-TD categorizes the consequences of TD symptoms into multiple functional domains: social, psychological/psychiatric, physical and vocational/educational/recreational.
  • The consensus panel and published statement were sponsored by an independent medical grant from Teva.

Neuronetics Announces Data Confirming Efficacy in Treating Anxious Depression with NeuroStar® Advanced Therapy for Mental Health

Retrieved on: 
Tuesday, January 17, 2023
Neuronetics, The Journal of Clinical Psychiatry, TMS, Depression, Anxiety, Quality of life, FDA, GAD-7, MDD, Marketing, Patient, Grammatical mood, Journal, Research, STIM, Pharmaceutical industry

These 1,800 patients were treated with NeuroStar TMS in commercial clinics and represented a diversity of patients with MDD and moderate-to-severe anxiety symptoms.

Key Points: 
  • These 1,800 patients were treated with NeuroStar TMS in commercial clinics and represented a diversity of patients with MDD and moderate-to-severe anxiety symptoms.
  • Patients with anxious depression exhibited clinically meaningful anxiety symptom improvement and antidepressant effects.
  • “These results are impressive because they further illustrate the mental health benefits that NeuroStar TMS can provide for many patients with psychiatric disorders like anxious depression.
  • Having access to this large registry allows us to further the research and establish best practices for treating physicians.”
    Neuronetics received FDA clearance to treat anxious depression with NeuroStar Advanced Therapy in July 2022.

Autobahn Therapeutics Announces Initiation of a Phase 1 Clinical Trial of ABX-002 for the Treatment for Major Depressive Disorder

Retrieved on: 
Tuesday, November 29, 2022
Mental Health, Health, Other Health, Clinical Trials, General Health, Biotechnology, PMID, PK, Pharmacokinetics, Tissue, Therapy, Brain, Physician, Caregiver, Patient, The Journal of Clinical Psychiatry, Grief, Magnetic resonance, Central nervous system disease, Serotonin, Disability, Autobahn, Grammatical mood, CNS, Depression, Suicide, Learned helplessness, Trial of the century, Safety, MDD, Pharmaceutical industry

Autobahn Therapeutics, a biotechnology company focused on restoring hope for people affected by CNS disorders, today announced the initiation of dosing in the companys Phase 1 clinical trial of ABX-002 in healthy volunteers.

Key Points: 
  • Autobahn Therapeutics, a biotechnology company focused on restoring hope for people affected by CNS disorders, today announced the initiation of dosing in the companys Phase 1 clinical trial of ABX-002 in healthy volunteers.
  • ABX-002 is a potent and selective, brain-boosting thyroid receptor beta (TR) agonist that Autobahn is evaluating as a potential adjunctive treatment for people with major depressive disorder (MDD) who are experiencing an inadequate response to their antidepressant.
  • We look forward to advancing ABX-002 in the clinic as we further our understanding of its potential impact for patients.
  • Inadequate Response to Treatment in Major Depressive Disorder: Augmentation and Adjunctive Strategies.

KetaMD Expands Access to Breakthrough Ketamine Therapy in Florida to Battle the Growing Mental Health Crisis and Shortage of Mental Health Care Providers

Retrieved on: 
Tuesday, October 4, 2022
Post-traumatic stress disorder, OTC, National Alliance on Mental Illness, Anxiety, News, Tropical Storm Ian, Telehealth, Lists of diseases, Euro-Excellence Inc v Kraft Canada Inc, National Alliance, Psychiatry, National Helping Families in Mental Health Crisis Day, National Suicide Prevention Week, Psilocybin, CEO, Ketamine, Population, CSE, Multimedia, Disorder, COVID-19, Mental disorder, Risk, Awareness, Growth, CDSA, The Journal of Clinical Psychiatry, Clifford Whittingham Beers, Rapids, Quality of life, Controlled Drugs and Substances Act, Journal, Suicidal ideation, Patient, Person, Drug prohibition law, Diagnosis, Removal of cannabis from Schedule I of the Controlled Substances Act, Forward-looking statement, Intention, Mental health, Depression, Company, Mental Illness Awareness Week, Pharmaceutical industry, Medicine, Audit

KetaMD is committed to battling the growing mental health crisis and alleviating the growing shortage of mental health care providers in Florida and across America, both issues further exacerbated by the COVID-19 pandemic.

Key Points: 
  • KetaMD is committed to battling the growing mental health crisis and alleviating the growing shortage of mental health care providers in Florida and across America, both issues further exacerbated by the COVID-19 pandemic.
  • Mental Health Crisis by the Numbers:
    1 in 5 U.S. adults experience mental illness each year.
  • Over 6.3 million people in Florida live in a community that does not have enough mental health professionals.
  • Florida ranks 49th in the nation for access to mental health care, according to Mental Health America.

MediPharm Labs Enters Cannabis Research Agreement with Keck School of Medicine of USC

Retrieved on: 
Tuesday, August 9, 2022
CEO, Dementia, Good, TSX, Annual report, Research, Clinical trial, Keck School of Medicine of USC, Patient, Cannabis, Synthetic cannabinoids, Libby, Sponsor, National Institute on Aging, MD, OTCQX, FSE, Diagnosis, Enhanced Defense Cooperation Agreement, Agitation, Partnership, API, Hospital, Meta-analysis, National Institute, THC, Caregiver, The Journal of Clinical Psychiatry, Compliance, CNS Drugs (journal), Medication, Harvard Medical School, Ageing, ACTC, Alzheimer's Association, Mayo Clinic, Cone Health Women's Hospital, USC, Aggression, Principal investigator, Hospice, Quality of life, Company, CBD, Treatment, National, MBA, ISO, University, Adoption, Pharmaceutical industry, Medicinal plants, Medicine, Brigham, Alzheimer's disease

David Pidduck, CEO, MediPharm Labs commented, "We are proud to participate in this important research that further solidifies our pharmaceutical approach to medical cannabis.

Key Points: 
  • David Pidduck, CEO, MediPharm Labs commented, "We are proud to participate in this important research that further solidifies our pharmaceutical approach to medical cannabis.
  • This trial benefits from passionate lead investigators, a world-renowned sponsor institution and funding from the US National Institute of Health.
  • In this project, Keck School of Medicine has chosen to use a combination of two medications, THC and CBD.
  • Alzheimer's Clinical Trials Consortium(ACTC) is funded by a Cooperative Agreement from the National Institute on Aging, National Institutes of Health.

Axsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in The Journal of Clinical Psychiatry

Retrieved on: 
Tuesday, May 31, 2022
Department, The Journal of Clinical Psychiatry, Lists of diseases, MDD, Journal, Patient, NASDAQ, Therapy, ASCEND, Depression, Dean (education), The American Journal of Psychiatry, Grammatical mood, CNS, Central nervous system, Major depressive disorder, Safety, Translational research, NMDA, NDA, American Journal, GEMINI, Massachusetts General Hospital, Harvard Medical School, Diagnosis, MD, GLOBE, Pharmaceutical industry, MADRS

The article, Efficacy and Safety of AXS-05 (dextromethorphan-bupropion) in Patients with Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI), was published in The Journal of Clinical Psychiatry and is available in full here .

Key Points: 
  • The article, Efficacy and Safety of AXS-05 (dextromethorphan-bupropion) in Patients with Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI), was published in The Journal of Clinical Psychiatry and is available in full here .
  • We are very pleased with the publication of the pivotal GEMINI trial results in The Journal of Clinical Psychiatry, a leading scientific journal, less than two weeks after the publication of the pivotal ASCEND trial results in The American Journal of Psychiatry, said Herriot Tabuteau, MD, Chief Executive Officer of Axsome.
  • The article was published online in The Journal of Clinical Psychiatry in advance of the corresponding upcoming print issue.
  • A new drug application (NDA) for AXS-05 for the treatment of major depressive disorder is under review by the FDA.

Analysis Group Is First to Describe Economic Burden for Patients with Acute Suicidal Ideation Tied to Major Depressive Disorder

Retrieved on: 
Tuesday, April 12, 2022
Lists of diseases, Patient, Analysis Group, Major depressive disorder, Behavior, PPPM, Epidemiology, Government, MDD, Janssen, COVID-19, Adult, Population, MDSI, ED, SIB, Research, Principal investigator, Suicide, Janssen Pharmaceuticals, United States Public Health Service, Johnson & Johnson, Health, Carmine, Journal, HRU, The Journal of Clinical Psychiatry, Psychotherapy, Physician, Industry, Risk, Time, Pharmaceutical industry, Hospital, Health insurance

BOSTON , April 12, 2022 /PRNewswire/ -- Researchers from Analysis Group, a global leader in health economics and outcomes research (HEOR), and the Janssen Pharmaceutical Companies of Johnson & Johnson have authored the first study to describe the economic burden of MDSI, or diagnosed major depressive disorder (MDD) with acute suicidal ideation or behavior (SIB). The study, published in the Journal of Clinical Psychiatry, is timely given the emerging evidence of negative effects of the COVID-19 pandemic on psychological health, and underscores the need for strategies to identify and treat at-risk patients for whom personalized pharmacological and non-pharmacological therapies may prevent a crisis.   

Key Points: 
  • First-of-its-kind study describes costs associated with major depressive disorder with acute suicidal ideation.
  • Inpatient admissions were 158 times higher within 1 month following the event, and 28 times higher within 12 months.
  • Substantial economic burden associated with MDSI persisted in the 12 months following the SIB event.
  • The study, titled "Economic Burden of Commercially Insured Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior in the United States," was published in April by the Journal of Clinical Psychiatry.